Metagenomi enters $75M at-the-market equity distribution agreement with Jefferies

Metagenomi Therapeutics, Inc.

Agreement with Jefferies to sell up to $75M of common stock via ATM offerings on Nasdaq.
Company is not obligated to sell any shares; sales are at Metagenomi's sole discretion.
Jefferies will receive a commission of up to 3.0% of gross proceeds from shares sold.
Shares to be offered under a new S-3 registration statement filed March 17, 2025.
No specific use of proceeds disclosed; proceeds may fund operations or R&D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.